BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 18398611)

  • 1. A novel phenotypic method to determine fludarabine triphosphate accumulation in T-lymphocytes from hematopoietic cell transplantation patients.
    Woodahl EL; Wang J; Heimfeld S; Sandmaier BM; O'Donnell PV; Phillips B; Risler L; Blough DK; McCune JS
    Cancer Chemother Pharmacol; 2009 Feb; 63(3):391-401. PubMed ID: 18398611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of fludarabine pharmacokinetic/dynamic biomarkers with donor chimerism in nonmyeloablative HCT recipients.
    McCune JS; Mager DE; Bemer MJ; Sandmaier BM; Storer BE; Heimfeld S
    Cancer Chemother Pharmacol; 2015 Jul; 76(1):85-96. PubMed ID: 25983023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intracellular disposition of fludarabine triphosphate in human natural killer cells.
    Woodahl EL; Wang J; Heimfeld S; Sandmaier BM; McCune JS
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):959-64. PubMed ID: 18781301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imatinib inhibition of fludarabine uptake in T-lymphocytes.
    Woodahl EL; Wang J; Heimfeld S; Ren AG; McCune JS
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):735-9. PubMed ID: 18004569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular pharmacology of fludarabine triphosphate in chronic lymphocytic leukemia cells during fludarabine therapy.
    Gandhi V; Kemena A; Keating MJ; Plunkett W
    Leuk Lymphoma; 1993 May; 10(1-2):49-56. PubMed ID: 8374523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular and clinical pharmacology of fludarabine.
    Gandhi V; Plunkett W
    Clin Pharmacokinet; 2002; 41(2):93-103. PubMed ID: 11888330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
    Gandhi V; Estey E; Du M; Keating MJ; Plunkett W
    Clin Cancer Res; 1997 Sep; 3(9):1539-45. PubMed ID: 9815841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia.
    Gandhi V; Kemena A; Keating MJ; Plunkett W
    Cancer Res; 1992 Feb; 52(4):897-903. PubMed ID: 1737352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and Model-Based Dosing to Optimize Fludarabine Therapy in Pediatric Hematopoietic Cell Transplant Recipients.
    Ivaturi V; Dvorak CC; Chan D; Liu T; Cowan MJ; Wahlstrom J; Stricherz M; Jennissen C; Orchard PJ; Tolar J; Pai SY; Huang L; Aweeka F; Long-Boyle J
    Biol Blood Marrow Transplant; 2017 Oct; 23(10):1701-1713. PubMed ID: 28684371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pilot pharmacologic biomarker study of busulfan and fludarabine in hematopoietic cell transplant recipients.
    McCune JS; Woodahl EL; Furlong T; Storer B; Wang J; Heimfeld S; Deeg HJ; O'Donnell PV
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):263-72. PubMed ID: 21909959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
    Gandhi V; Estey E; Du M; Nowak B; Keating MJ; Plunkett W
    Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous quantification of busulfan, clofarabine and F-ARA-A using isotope labelled standards and standard addition in plasma by LC-MS/MS for exposure monitoring in hematopoietic cell transplantation conditioning.
    Punt AM; Langenhorst JB; Egas AC; Boelens JJ; van Kesteren C; van Maarseveen EM
    J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Jun; 1055-1056():81-85. PubMed ID: 28445850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fludarabine-mediated circumvention of cytarabine resistance is associated with fludarabine triphosphate accumulation in cytarabine-resistant leukemic cells.
    Yamamoto S; Yamauchi T; Kawai Y; Takemura H; Kishi S; Yoshida A; Urasaki Y; Iwasaki H; Ueda T
    Int J Hematol; 2007 Feb; 85(2):108-15. PubMed ID: 17321987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential induction of apoptosis by fludarabine monophosphate in leukemic B and normal T cells in chronic lymphocytic leukemia.
    Consoli U; El-Tounsi I; Sandoval A; Snell V; Kleine HD; Brown W; Robinson JR; DiRaimondo F; Plunkett W; Andreeff M
    Blood; 1998 Mar; 91(5):1742-8. PubMed ID: 9473241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of intracellular fludarabine triphosphate in human peripheral blood mononuclear cells by LC-MS/MS.
    Huang L; Lizak P; Aweeka F; Long-Boyle J
    J Pharm Biomed Anal; 2013 Dec; 86():198-203. PubMed ID: 24013121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro cytotoxic effects of fludarabine (2-F-ara-A) in combination with commonly used antileukemic agents by isobologram analysis.
    Kano Y; Akutsu M; Tsunoda S; Suzuki K; Ichikawa A; Furukawa Y; Bai L; Kon K
    Leukemia; 2000 Mar; 14(3):379-88. PubMed ID: 10720130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Personalized fludarabine dosing to reduce nonrelapse mortality in hematopoietic stem-cell transplant recipients receiving reduced intensity conditioning.
    Sanghavi K; Wiseman A; Kirstein MN; Cao Q; Brundage R; Jensen K; Rogosheske J; Kurtzweil A; Long-Boyle J; Wagner J; Warlick ED; Brunstein CG; Weisdorf DJ; Jacobson PA
    Transl Res; 2016 Sep; 175():103-115.e4. PubMed ID: 27094990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of fludarabine in hematological malignancies.
    Montillo M; Ricci F; Tedeschi A
    Expert Rev Anticancer Ther; 2006 Sep; 6(9):1141-61. PubMed ID: 17020450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A limited sampling schedule to estimate individual pharmacokinetic parameters of fludarabine in hematopoietic cell transplant patients.
    Salinger DH; Blough DK; Vicini P; Anasetti C; O'Donnell PV; Sandmaier BM; McCune JS
    Clin Cancer Res; 2009 Aug; 15(16):5280-7. PubMed ID: 19671874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of fludarabine and arabinosylcytosine for treatment of chronic lymphocytic leukemia: clinical efficacy and modulation of arabinosylcytosine pharmacology.
    Gandhi V; Robertson LE; Keating MJ; Plunkett W
    Cancer Chemother Pharmacol; 1994; 34(1):30-6. PubMed ID: 8174200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.